

**MELoxicam, meloxicam tablet**  
**MELVETRAK, INC.**

**HIGHLIGHTS OF PRESCRIBING INFORMATION**  
These highlights do not include all the information needed to use MELoxicam TABLETS USP safely and effectively. See full prescribing information for MELoxicam TABLETS USP.

**MELoxicam Tablet USP, for oral use**  
United States Approved 2008

**WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS**  
See full prescribing information for complete boxed warning.  
• **Nonsteroidal anti-inflammatory drugs (NSAIDs)** cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (5.1)  
• **Meloxicam tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (6.2)**  
• **NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur with or without warning, and may occur without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (5.2)**

**RECENT MAJOR CHANGES**  
Boxed Warning (2.0)  
Indications and Usage, Juvenile Rheumatoid Arthritis (RA) Pauciarticular and Polyarticular Course (1, 2.0)(2.0.0)  
Dosage and Administration, General Dosing Instructions (1, 2.1)(2.1.0)  
Warnings and Precautions, Cardiovascular Thrombotic Events (5.1)(5.1.0)  
Warnings and Precautions, Heart Failure and Edema (5.2)(5.2.0)

**INDICATIONS AND USAGE**  
Meloxicam tablets are a non-steroidal anti-inflammatory drug indicated for:  
• Osteoarthritis (OA) (1)  
• Rheumatoid Arthritis (RA) (2)  
• Juvenile Rheumatoid Arthritis (RA) in patients who weigh  $\geq 60$  kg (1, 2)

**DOSE AND ADMINISTRATION**  
Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (2.1)  
• **OA (2.0)(2.0.0)**  
Starting dose: 7.5 mg once daily  
Dose may be increased to 15 mg once daily  
• **RA (2.0)**  
7.5 mg once daily in children  $\geq 6$  kg

Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam. Even the total milligram strength is not the same (5.0)  
**DOSE FORMS AND STRENGTHS**  
• Meloxicam Tablets USP 7.5 mg and 15 mg (3)

**CONTRAINDICATIONS**  
• Known hypersensitivity to meloxicam or any components of the drug product (4)  
• History of asthma, urticaria, or other drug-type reactions involving aspirin or other NSAIDs (4)  
• In the setting of CABG surgery (4)

**WARNINGS AND PRECAUTIONS**  
• **Cardiovascular** - Taking aspirin or other platelet-inhibiting agents with meloxicam increases the risk of bleeding (5.1)  
• **Hypertension** - Patients taking some antihypertensive medications may have impaired response to these therapies (5.2)  
• **Fluid Retention and Edema** - Avoid use of Meloxicam in patients with severe heart failure unless benefits are expected to outweigh the risk of worsening heart failure (5.2)  
• **Renal Impairment** - Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypotension. Avoid use of Meloxicam in patients with advanced renal disease unless benefits are expected to outweigh the risk of worsening renal function (5.2)  
• **Anaphylactic Reactions** - See warnings on help of an anaphylactic reaction occur (5.7)  
• **Aspirin-Related Reactions** - Avoid concurrent use of aspirin with meloxicam in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (5.8)  
• **Aspirin-Related Reactions** - Avoid concurrent use of aspirin with meloxicam in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (5.8)  
• **Aspirin-Related Reactions** - Avoid use of aspirin with meloxicam in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (5.8)  
• **Aspirin-Related Reactions** - Avoid use of aspirin with meloxicam in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (5.8)  
• **Aspirin-Related Reactions** - Avoid use of aspirin with meloxicam in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (5.8)  
• **Aspirin-Related Reactions** - Avoid use of aspirin with meloxicam in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (5.8)

**ADVERSE REACTIONS**  
• Most common (10% and above) have typically observed adverse events include: headache, upper respiratory tract infection, dizziness, and influenza-like symptoms (6.1)  
• Adverse events observed in patients studies were similar to those in the adult clinical trial experience (6.1)

**DRUG INTERACTIONS**  
• **Aspirin** - Concurrent use of aspirin with meloxicam increases the risk of bleeding (5.1)  
• **Aspirin** - Concurrent use of aspirin with meloxicam increases the risk of bleeding (5.1)  
• **Aspirin** - Concurrent use of aspirin with meloxicam increases the risk of bleeding (5.1)  
• **Aspirin** - Concurrent use of aspirin with meloxicam increases the risk of bleeding (5.1)

**USE IN SPECIFIC POPULATIONS**  
• **Pregnancy** - Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation (5.1)(8.1)  
• **Lactation** - Meloxicam is excreted with variable intensity. Consider withdrawal of Meloxicam in women who have children nursing (6.3)

See full prescribing information for complete boxed warning.  
Revised: 2/2018

**FULL PRESCRIBING INFORMATION: CONTENTS\***  
**1 INDICATIONS AND USAGE**  
1.1 Osteoarthritis (OA)  
1.2 Rheumatoid Arthritis (RA)  
1.3 Juvenile Rheumatoid Arthritis (RA) Pauciarticular and Polyarticular Course  
**2 DOSAGE AND ADMINISTRATION**  
2.1 General Dosing Instructions  
2.2 Osteoarthritis  
2.3 Rheumatoid Arthritis  
2.4 Juvenile Rheumatoid Arthritis (RA) Pauciarticular and Polyarticular Course  
2.5 Renal Impairment  
2.6 Non-Interchangeability with Other Formulations of Meloxicam  
**3 DOSE FORMS AND STRENGTHS**  
**4 CONTRAINDICATIONS**  
**5 WARNINGS AND PRECAUTIONS**  
5.1 Cardiovascular Thrombotic Events  
5.2 Gastrointestinal Bleeding, Ulceration, and Perforation  
5.3 Hypertension  
5.4 Hypervolemia  
5.5 Heart Failure and Edema  
5.6 Renal Toxicity and Hyperkalemia  
5.7 Anaphylactic Reactions  
5.8 Exacerbation of Asthma Related to Aspirin Sensitivity  
5.9 Systemic Skin Reactions  
5.10 Premature Closure of Fetal Ductus Arteriosus  
5.11 Hematologic Toxicity  
5.12 Masking of Inflammation and Fever  
5.13 Laboratory Monitoring  
**6 ADVERSE REACTIONS**  
6.1 Clinical Trial Experience  
6.2 Post-Marketing Experience  
**7 DRUG INTERACTIONS**  
**8 USE IN SPECIFIC POPULATIONS**  
8.1 Pregnancy  
8.2 Lactation  
8.3 Fertility and Modes of Reproductive Potential  
8.4 Pediatric Use  
8.5 Geriatric Use  
8.6 Hepatic Impairment  
8.7 Renal Impairment  
**10 OVERDOSAGE**  
**11 DESCRIPTION**  
**12 CLINICAL PHARMACOLOGY**  
12.1 Mechanism of Action  
12.3 Pharmacokinetics  
**13 NONCLINICAL TOXICOLOGY**  
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility  
**14 CLINICAL STUDIES**  
14.1 Osteoarthritis and Rheumatoid Arthritis  
14.2 Juvenile Rheumatoid Arthritis (RA) Pauciarticular and Polyarticular Course  
**16 HOW SUPPLIED/STORAGE AND HANDLING**  
**17 PATIENT COUNSELING INFORMATION**  
\* Section or subsection omitted from the full prescribing information are not listed.

**FULL PRESCRIBING INFORMATION**  
**WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS**  
**Cardiovascular Thrombotic Events**  
• **Nonsteroidal anti-inflammatory drugs (NSAIDs)** cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see Warnings and Precautions (5.1)).  
• **Meloxicam tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see Contraindications (4) and Warnings and Precautions (5.1)).**  
**Gastrointestinal Bleeding, Ulceration, and Perforation**  
• **NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur with or without warning, and may occur without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (see Warnings and Precautions (5.2)).**

**INDICATIONS AND USAGE**  
**1.1 Osteoarthritis (OA)**  
Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1)].  
**1.2 Rheumatoid Arthritis (RA)**  
Meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1)].  
**1.3 Juvenile Rheumatoid Arthritis (RA) Pauciarticular and Polyarticular Course**  
Meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile Rheumatoid Arthritis in patients who weigh  $\geq 60$  kg [see Dosage and Administration (2.4) and Clinical Studies (14.2)].  
**2 DOSAGE AND ADMINISTRATION**  
**2.1 General Dosing Instructions**  
Carefully consider the potential benefits and risks of Meloxicam tablets and other treatment options before deciding to use Meloxicam tablets. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)]. Also observing the response to initial therapy with Meloxicam tablets, adjust the dose to suit an individual patient's needs.  
In adults, the maximum recommended daily oral dose of Meloxicam tablets is 15 mg regardless of formulation. In patients with renal impairment, a maximum daily dosage of 7.5 mg is recommended [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. Meloxicam tablets may be taken without regard to timing of meals.  
**2.2 Osteoarthritis**  
For the relief of the signs and symptoms of osteoarthritis the recommended starting and maintenance oral dose of Meloxicam tablets is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.  
**2.3 Rheumatoid Arthritis**  
For the relief of the signs and symptoms of rheumatoid arthritis, the recommended starting and maintenance oral dose of Meloxicam tablets is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.  
**2.4 Juvenile Rheumatoid Arthritis (RA) Pauciarticular and Polyarticular Course**  
For the treatment of juvenile rheumatoid arthritis, the recommended oral dose of Meloxicam tablets is 7.5 mg once daily in children who weigh  $\geq 60$  kg. There is no additional benefit demonstrated by increasing the dose above 7.5 mg in clinical trials. Meloxicam tablets should not be used in children who weigh  $< 60$  kg.  
**2.5 Renal Impairment**  
The use of Meloxicam tablets in subjects with severe renal impairment is not recommended.  
In patients on hemodialysis, the maximum dosage of Meloxicam tablets is 7.5 mg per day [see Clinical Pharmacology (12.3)].  
**2.6 Non-Interchangeability with Other Formulations of Meloxicam**  
Meloxicam tablets have not shown equivalent systemic exposure to other approved formulations of oral meloxicam product even if the total milligram strength is the same. Do not substitute similar dose strengths of Meloxicam tablets with other formulations of oral meloxicam product.  
**3 DOSE FORMS AND STRENGTHS**  
Meloxicam Tablets USP:  
• 7.5 mg: Light yellow, round flat beveled edged, tablet with U & 1 debossed on one side and 75 debossed centrally on the other side.  
• 15 mg: Light yellow, capsule shaped, biconvex, tablet with U & 1 debossed on one side and 15 debossed centrally on the other side.

#### 4 CONTRAINDICATIONS

Meloxicam is contraindicated in the following patients:

- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any component of the drug product [ see Warnings and Precautions ( 2.7, 5.9) ]
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [ see Warnings and Precautions ( 2.7, 5.9) ]
- In the setting of coronary artery bypass graft (CABG) surgery [ see Warnings and Precautions ( 5.1) ]

#### 5 WARNINGS AND PRECAUTIONS

##### 5.1 Cardiovascular Thrombotic Events

Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three-year duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for the CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar among users with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began early in the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.

To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the signs to take if they occur.

There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as meloxicam, increases the risk of serious gastrointestinal (GI) event [ see Warnings and Precautions ( 5.2) ].

##### 5.2 Postoperative Acute Myocardial Infarction (AMI) Risks

Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [ see Contraindications ( 4) ].

##### 5.3 MI Risks

Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this case cohort, the incidence of death in the first-year post-MI was 20 per 100 persons/year in NSAID-treated patients compared to 12 per 100 persons/year in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.

Avoid the use of Meloxicam in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If Meloxicam is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

##### 5.2 Gastrointestinal Bleeding, Ulceration, and Perforation

NSAIDs, including meloxicam, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms. Patients treated with NSAIDs, only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.

##### 5.3 Risk Factors for GI Bleeding, Ulceration, and Perforation

Patients with a prior history of peptic ulcer disease and/or GI bleeding, who used NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleed in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most gastrointestinal events of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.

##### 5.4 Strategies to Minimize the GI Risks in NSAID-treated patients

- Use the lowest effective dosage for the shortest possible duration.
- Avoid administration of more than one NSAID at a time.
- Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs.
- Remains alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy.
- If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue Meloxicam until a serious GI adverse event is ruled out.
- In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding [ see Drug Interactions ( 7) ].

##### 5.3 Hepatotoxicity

Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs, including meloxicam.

Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs, including meloxicam.

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue Meloxicam immediately, and perform a clinical evaluation of the patient [ see Use in Specific Populations ( 8.6) and Clinical Pharmacology ( 12.3) ].

##### 5.4 Hypertension

NSAIDs, including Meloxicam, can lead to a new onset or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, diuretic diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs [ see Drug Interactions ( 7) ].

Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.

##### 5.5 Heart Failure and Edema

The Cardiovascular and Endothelial Tissue Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalization for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.

Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of meloxicam may blunt the CV effect of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [ see Drug Interactions ( 7) ].

Avoid the use of Meloxicam in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If Meloxicam is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

##### 5.6 Renal Toxicity and Hypokalemia

Long-term administration of NSAIDs, including Meloxicam, has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury.

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation, which can result in acute renal insufficiency, hypokalemia, and renal papillary necrosis, or other serious complications. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

The renal effects of Meloxicam may mask the progression of renal dysfunction in patients with pre-existing renal disease. Because some Meloxicam metabolites are excreted by the kidney, monitor patients for signs of worsening renal function.

Correct volume status in dehydrated or hypovolemic patients prior to initiating Meloxicam. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of Meloxicam [ see Drug Interactions ( 7) ].

No information is available from controlled clinical studies regarding the use of Meloxicam in patients with advanced renal disease. Avoid the use of Meloxicam in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If Meloxicam is used in patients with advanced renal disease, monitor patients for signs of worsening renal function [ see Clinical Pharmacology ( 12.3) ].

##### Hypokalemia

Increases in serum potassium concentration, including hypokalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.

##### 5.7 Anaphylactic Reactions

Meloxicam has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma [ see Contraindications ( 4) and Warnings and Precautions ( 5.9) ].

Seek emergency help if an anaphylactic reaction occurs.

##### 5.8 Exacerbation of Asthma Related to Aspirin Sensitivity

A subgroup of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe, potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, Meloxicam is contraindicated in patients with this form of aspirin sensitivity [ see Contraindications ( 4) ]. When Meloxicam is used in patients with pre-existing asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.

##### 5.9 Serious Skin Reactions

NSAIDs, including meloxicam, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and discontinue the use of Meloxicam at the first appearance of skin rash or any other sign of hypersensitivity. Meloxicam is contraindicated in patients with previous serious skin reactions to NSAIDs [ see Contraindications ( 4) ].

##### 5.10 Prevention Closure of Fetal Ductus Arteriosus

Meloxicam may cause premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including Meloxicam, in pregnant women starting at 30 weeks of gestation (third trimester) [ see Use in Specific Populations ( 8.1) ].

##### 5.11 Hematologic Toxicity

Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an idiosyncratic decrease in erythropoiesis. If a patient treated with Meloxicam has any sign or symptoms of anemia, monitor hemoglobin or hematocrit.

NSAIDs, including Meloxicam, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concurrent use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (NRNIs) may increase this risk. Monitor these patients for signs of bleeding [ see Drug Interactions ( 7) ].

##### 5.12 Masking of Inflammation and Fever

The pharmacological activity of Meloxicam in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infection.

##### 5.13 Laboratory Monitoring

Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [ see Warnings and Precautions ( 5.2, 5.3, 5.6) ].

#### 6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

- Cardiovascular Thrombotic Events [ see Banned Warning and Warnings and Precautions ( 5.1) ]
- GI Bleeding, Ulceration, and Perforation [ see Banned Warning and Warnings and Precautions ( 5.2) ]
- Hypertension [ see Warnings and Precautions ( 5.3) ]
- Hypokalemia [ see Warnings and Precautions ( 5.4) ]
- Heart Failure and Edema [ see Warnings and Precautions ( 5.5) ]
- Renal Toxicity and Hypokalemia [ see Warnings and Precautions ( 5.6) ]
- Anaphylactic Reactions [ see Warnings and Precautions ( 5.7) ]
- Serious Skin Reactions [ see Warnings and Precautions ( 5.9) ]
- Hematologic Toxicity [ see Warnings and Precautions ( 5.11) ]

##### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

##### Adults

##### Dose-toxicity and Rheumatoid Arthritis

The Meloxicam Phase 2-3 clinical trial database includes 10,122 OA patients and 1012 RA patients treated with Meloxicam 7.5 mg/day, 1505 OA patients and 151 RA patients treated with Meloxicam 15 mg/day. Meloxicam dose-toxicity was observed in these patients in at least one study and in 312 patients for at least one year. Approximately 10,500 of these patients were treated in ten placebo- and/or active-controlled observational trials, and 283 of these patients were treated in placebo- and/or active-controlled observational trials. Gastrointestinal (GI) adverse events were the most



NSAID.

#### Pharmacokinetics

-

#### Labor or Delivery

There are no studies on the effects of Meloxicam during labor or delivery. In animal studies, NSAIDs, including meloxicam, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth.

#### Data

-

#### Animal Data

Meloxicam was not teratogenic when administered to pregnant rats during fetal organogenesis at oral doses up to 4 mg/kg/day (2.6-fold greater than the MRHD of 15 mg of meloxicam based on BSA comparison). Administration of meloxicam to pregnant rabbits throughout embryogenesis produced an increased incidence of septal defects of the heart at an oral dose of 60 mg/kg/day (78-fold greater than the MRHD based on BSA comparison). The no effect level was 20 mg/kg/day (26-fold greater than the MRHD based on BSA comparison). In rats and rabbits, embryofetality occurred at oral meloxicam doses of 1 mg/kg/day and 1 mg/kg/day, respectively (0.6-fold greater, respectively, than the MRHD based on BSA comparison) when administered throughout organogenesis.

Oral administration of meloxicam to pregnant rats during gestation through lactation increased the incidence of dystocia, delayed parturition, and decreased offspring survival at meloxicam doses of 0.125 mg/kg/day or greater (0.08-times MRHD based on BSA comparison).

#### 2.1 Lactation

##### Risk Summary

There are no human data available on whether meloxicam is present in human milk, or on the effects on breastfed infants, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Meloxicam and any potential adverse effects on the breastfed infant from the Meloxicam from the underlying maternal condition.

#### Data

##### Animal Data

Meloxicam was present in the milk of lactating rats at concentrations higher than those in plasma.

#### 2.2 Females and Males of Reproductive Potential

##### Females

Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including Meloxicam, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Published animal studies have shown that administration of prostaglandin synthase inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Consider withdrawal of NSAIDs, including Meloxicam, in women who have difficulties conceiving or who are undergoing investigation of infertility.

##### 2.3 Pediatric Use

The safety and effectiveness of meloxicam in pediatric JRA patients from 2 to 17 years of age has been evaluated in three clinical trials (see Dosage and Administration (2.3), Adverse Reactions (4.1) and Clinical Studies (4.2.1)).

##### 2.4 Geriatric Use

Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects (see Warnings and Precautions (5.1, 5.2, 5.3, 5.6, 7.1)).

##### 2.5 Hepatic Impairment

No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment have not been adequately studied. Since meloxicam is significantly metabolized in the liver and hepatotoxicity may occur, use meloxicam with caution in patients with hepatic impairment (see Warnings and Precautions (5.3) and Clinical Pharmacology (7.2.3)).

##### 2.6 Renal Impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been studied. The use of Meloxicam in subjects with severe renal impairment is not recommended. In patients on hemodialysis, meloxicam should not exceed 7.5 mg per day. Meloxicam is not dialyzable (see Dosage and Administration (2.3) and Clinical Pharmacology (7.2.3)).

#### 10 OVERDOSAGE

Symptoms following acute NSAID overdosage have been typically limited to headache, dizziness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare (see Warnings and Precautions (5.1, 5.2, 5.4, 5.6)).

Monitor patients with symptoms and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (50 to 100 g in adults, 1 to 2 g per kg of body weight in pediatric patients under 16 years of age) in symptomatic patients who ingest four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.

There is limited experience with meloxicam overdosage. Cholestyramine is known to accelerate the clearance of meloxicam. Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdosage.

For additional information about overdosage treatment, call a poison control center (1-800-222-1222).

#### 11 DESCRIPTION

Meloxicam Tablets USP are a nonsteroidal anti-inflammatory drug (NSAID). Each tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as cholesteryl-2-merhyl-7-(5-merhyl-2-thienyl)-2-[4-(1,2-dioxo-3-thioxo-3-carbamido-1,3-dioxole)]. The molecular weight is 321.4. Its empirical formula is C<sub>18</sub>H<sub>15</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub> and it has the following structural formula:



Meloxicam is a pale yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P<sub>ow</sub>) of 1.1 in octanol-buffer (pH 7.4). Meloxicam has pKa values of 1.1 and 4.2.

Meloxicam is available as a tablet for oral administration containing 7.5 mg or 15 mg meloxicam.

The inactive ingredients in Meloxicam tablets USP include colloidal silicon dioxide, croscopolone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and sodium citrate dihydrate.

#### 12 CLINICAL PHARMACOLOGY

##### 12.1 Mechanism of Action

Meloxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Meloxicam is a potent inhibitor of prostaglandin synthesis *in vivo*. Meloxicam concentrations reached during therapy have produced *in vivo* effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because meloxicam is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandin in peripheral tissues.

##### 12.2 Pharmacokinetics

###### Absorption

The absolute bioavailability of meloxicam capsules was 99% following a single oral dose of 30 mg compared with 30 mg IV bolus injection. Following single intravenous doses, dose-proportional pharmacokinetics were shown in the range of 5 to 15 mg. After multiple oral doses, the pharmacokinetics of meloxicam capsules were dose-proportional over the range of 7.5 mg to 15 mg. Mean C<sub>max</sub> was achieved within 1 to 2 hours after a 7.5 mg meloxicam tablet was administered under fasted conditions, indicating a prolonged drug absorption. With multiple dosing, steady-state concentrations were reached by Day 3. A second meloxicam concentration peak occurs around 12 to 14 hours post-dose, suggesting biliary recirculation.

Meloxicam capsules have been shown to be bioequivalent to Meloxicam tablets.

Table 4 Single Dose and Steady-State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam (Mean and % CV)\*

| Pharmacokinetic Parameters (% CV) | Steady State               |                | Single Dose            |                |
|-----------------------------------|----------------------------|----------------|------------------------|----------------|
|                                   | Healthy male adults (n=12) |                | Elderly females (n=12) |                |
|                                   | 7.5 mg tablets             | 15 mg capsules | 15 mg capsules         | 15 mg capsules |
| N                                 | 6                          | 6              | 6                      | 6              |
| C <sub>max</sub>                  | 106 (n=1)                  | 213 (6)        | 32 (24)                | 67 (18)        |
| C <sub>min</sub>                  | 0 (0)                      | 0 (0)          | 0 (0)                  | 0 (0)          |
| t <sub>1/2</sub>                  | 20.1 (29)                  | 21 (14)        | 18 (46)                | 16 (29)        |
| t <sub>1/2</sub> (fast)           | 8.8 (20)                   | 8.0 (7)        | 5.1 (22)               | 10 (44)        |
| t <sub>1/2</sub> (slow)           | 11.7 (14)                  | 11 (20)        | 25 (44)                | 21 (22)        |

\* The parameter values in the table are from various studies.  
n = number of patients.  
1 = Meloxicam tablets.  
3 = 15 mg (15 mg) capsules.

###### Food and Amount Effect

Administration of meloxicam capsules following a high fat breakfast (75% of fat) resulted in mean peak drug levels (i.e., C<sub>max</sub>) being increased by approximately 27% while the extent of absorption (AUC) was unchanged. The time to maximum concentration (T<sub>max</sub>) was achieved between 1 and 5 hours. No pharmacokinetic interaction was detected with concurrent administration of antacids. Based on these results, Meloxicam can be administered without regard to timing of meals or concurrent administration of antacids.

###### Distribution

The mean volume of distribution (V<sub>d</sub>) of meloxicam is approximately 10 L. Meloxicam is ~99.4% bound to human plasma proteins (primarily albumin) within the therapeutic dose range. The fraction of protein binding is independent of drug concentration, over the clinically relevant concentration range, but decreases to ~99% in patients with renal disease. Meloxicam penetration into human red blood cells, after oral dosing, is less than 10%. Following a radiolabeled dose, over 90% of the radioactivity detected in the plasma was present as unchanged meloxicam.

Meloxicam concentrations in synovial fluid, after a single oral dose, range from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 times higher than in plasma, due to the lower albumin content in synovial fluid as compared to plasma. The significance of this penetration is unknown.

###### Elimination

###### Metabolism

Meloxicam is extensively metabolized in the liver. Meloxicam metabolites include 7-carboxy meloxicam (60% of dose), from P-450 mediated metabolism formed by oxidation of an intermediate metabolite 5-hydroxymethyl meloxicam which also undergoes a lesser extent (9% of dose) *in vitro* studies indicate that CYP2C9 cytochrome P450 metabolizing enzyme plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme. Patients' peroxyl radical activity is probably responsible for the other two metabolites which account for 16% and 6% of the administered dose, respectively. All the four metabolites are not known to have any *in vitro* pharmacological activity. Excretion

Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extent in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The route of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 52%, 5%, and 12% of the dose were found in urine in the form of meloxicam, and the 5-hydroxymethyl and 7-carboxy metabolites, respectively. There is significant biliary and/or renal excretion of the drug. This was demonstrated when oral administration of cholestyramine following a single IV dose of meloxicam decreased the AUC of meloxicam by 50%.

The mean elimination half-life (t<sub>1/2</sub>) ranges from 13 hours to 20 hours. The elimination half-life is constant across dose levels indicating linear metabolism within the therapeutic dose range. Plasma clearance ranges from 7 to 9 mL/min.

###### Specific Populations

###### Pediatric

After single (0.25 mg/kg) dose administration and after achieving steady state (0.375 mg/kg/day), there was a general trend of approximately 30% lower exposure in younger patients (2 to 6 years old) as compared to the older patients (7 to 16 years old). The older patients had meloxicam exposures similar (single dose) or slightly reduced (steady state) to those in the adult patients, when using AUC values normalized by a dose of 0.25 mg/kg (see Dosage and Administration (2.4)). The meloxicam mean (SD) elimination half-life was 15.2 (10.1) and 13.0 hours (1.0) for the 2 to 6 year old patients, and 7 to 16 year old patients, respectively.

In a covariate analysis, utilizing population pharmacokinetics, body weight, but not age, was the single predictive covariate for differences in the meloxicam apparent plasma clearance. The body weight normalized apparent oral clearance values were adequate predictors of meloxicam exposure in pediatric patients.

The pharmacokinetics of Meloxicam in pediatric patients under 2 years of age have not been investigated.

###### Geriatric

Elderly males (≥65 years of age) exhibited meloxicam plasma concentrations and steady-state pharmacokinetics similar to young males. Elderly females (≥65 years of age) had a 47% higher AUC<sub>0-∞</sub> and 32% higher C<sub>max</sub> as compared to younger females (≤55 years of age) after body weight normalization. Despite the increased oral concentrations in the elderly females, the adverse event profile was comparable for both elderly patient populations. A smaller free fraction was found in elderly female patients in comparison to elderly male patients.

See

Young females exhibited slightly lower plasma concentrations relative to young males. After single doses of 7.5 mg Meloxicam, the mean elimination half-life was 19.5 hours for the female group as compared to 22.4 hours for the male group. At steady state, the data were similar (17.6 hours vs. 21.4 hours). This pharmacokinetic difference due to gender is likely to be of little clinical importance. There was linearity of pharmacokinetics and no appreciable difference in the C<sub>max</sub> or T<sub>max</sub> across genders.

#### Hepatic Impairment

Following a single 15 mg dose of meloxicam there was no marked difference in plasma concentrations in patients with mild (Child-Pugh Class I) or moderate (Child-Pugh Class II) hepatic impairment compared to healthy volunteers. Protein binding of meloxicam was not affected by hepatic impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment (Child-Pugh Class III) have not been adequately studied [see Warnings and Precautions (5.3) and Use in Specific Populations (6.6)].

#### Renal Impairment

Meloxicam pharmacokinetics have been investigated in subjects with mild and moderate renal impairment. Total drug plasma concentrations of meloxicam decreased and renal clearance of meloxicam increased with the degree of renal impairment while free AUC values were similar in all groups. The higher meloxicam clearance in subjects with renal impairment may be due to increased fractions of unbound meloxicam which is available for hepatic metabolism and subsequent excretion. No dosage adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been adequately studied. The use of Meloxicam in subjects with severe renal impairment is not recommended [see Dosage and Administration (2.5), Warnings and Precautions (5.6) and Use in Specific Populations (6.7)].

#### Hemodialysis

Following a single dose of meloxicam, the free C<sub>max</sub> plasma concentrations were higher in patients with renal failure on chronic hemodialysis (7% free fraction) in comparison to healthy volunteers (93% free fraction). Hemodialysis did not lower the total drug concentration in plasma; therefore, additional doses are not necessary after hemodialysis. Meloxicam is not dialyzable [see Dosage and Administration (2.1) and Use in Specific Populations (6.7)].

#### Drug Interactions/Studies

**Aspirin:** When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered. When Meloxicam is administered with aspirin (1000 mg three times daily) to healthy volunteers, it tended to increase the AUC (10%) and C<sub>max</sub> (24%) of meloxicam. The clinical significance of this interaction is not known. See Table 3 for clinically significant drug interactions of NSAIDs with aspirin [see Drug Interactions (7)].

**Cholestyramine:** Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicamly 50%. This results in decrease in t<sub>1/2</sub> from 19.5 hours to 12.5 hours, and a 30% reduction in AUC. This suggests the existence of a recirculation pathway for meloxicam in the gastrointestinal tract. The clinical relevance of this interaction has not been established.

**Cimetidine:** Concurrent administration of 200 mg cimetidine four times daily did not alter the single-dose pharmacokinetics of 30 mg meloxicam.

**Digoxin:** Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after intravenous administration for 7 days at clinical doses. In vivo testing found no protein binding displacement between digoxin and meloxicam.

**Lithium:** In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg twice daily with meloxicam 15 mg QD every day as compared to subjects receiving lithium alone [see Drug Interactions (7)].

**Mefenamic Acid:** A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of mefenamic acid once weekly. Meloxicam did not have a significant effect on the pharmacokinetics of single doses of mefenamic acid. In vivo, mefenamic acid did not displace meloxicam from its human serum binding sites [see Drug Interactions (7)].

**Warfarin:** The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. However, one subject showed an increase in INR from 1.5 to 2.1. Caution should be used when administering Meloxicam with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced [see Drug Interactions (7)].

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### Carcinogenesis

There was no increase in tumor incidence in long-term carcinogenicity studies in rats (104 weeks) and mice (93 weeks) administered meloxicam oral doses up to 0.8 mg/kg/day in rats and up to 8.0 mg/kg in mice (up to 5.5- and 2.2-times, respectively, the maximum recommended human dose [MRHD] of 15 mg/day Meloxicam based on body surface area [BSA] comparison).

#### Mutagenesis

Meloxicam was not mutagenic in an Ames assay, or clastogenic in a chromosome aberration assay with human lymphocytes and an in vivo micronucleus test in mouse bone marrow.

#### Impairment of Fertility

Meloxicam did not impair male and female fertility in rats at oral doses up to 9 mg/kg/day in males and 5 mg/kg/day in females (up to 3.8- and 3.2-times greater, respectively, than the MRHD based on BSA comparison).

## 14 CLINICAL STUDIES

### 14.1 Osteoarthritis and Rheumatoid Arthritis

The use of Meloxicam for the treatment of the signs and symptoms of osteoarthritis of the knee and hip was evaluated in a 12-week, double-blind, controlled trial. Meloxicam (7.5 mg, 15 mg, and 22.5 mg daily) was compared to placebo. The four primary endpoints were investigator's global assessment, patient global assessment, patient pain assessment, and WOMAC score (a self-administered questionnaire addressing pain, function, and stiffness). Patients on Meloxicam 7.5 mg daily and Meloxicam 15 mg daily showed significant improvement in each of these endpoints compared with placebo.

The use of Meloxicam for the management of signs and symptoms of osteoarthritis was evaluated in six double-blind, active-controlled trials outside the U.S. ranging from 4 weeks to 6 months' duration. In these trials, the efficacy of Meloxicam in doses of 7.5 mg/day and 15 mg/day was comparable to celecoxib 20 mg/day and diclofenac SR 100 mg/day and consistent with the efficacy seen in the U.S. trial.

The use of Meloxicam for the treatment of the signs and symptoms of rheumatoid arthritis was evaluated in a 12-week, double-blind, controlled multinational trial. Meloxicam (7.5 mg, 15 mg, and 22.5 mg daily) was compared to placebo. The primary endpoint in this study was the ACR20 response rate, a composite measure of clinical, laboratory, and functional measures of RA response. Patients receiving Meloxicam 7.5 mg and 15 mg daily showed significant improvement in the primary endpoint compared with placebo. No incremental benefit was observed with the 22.5 mg dose compared to the 15 mg dose.

### 14.2 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

The use of Meloxicam for the treatment of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older was evaluated in two 12-week, double-blind, parallel-arm, active-controlled trials.

Both studies included three arms: naproxen and two doses of meloxicam. In both studies, meloxicam dosing began at 0.25 mg/kg/day (7.5 mg maximum) or 0.25 mg/kg/day (15 mg maximum), and naproxen dosing began at 10 mg/kg/day. One study used these doses throughout the 12-week dosing period, while the other incorporated a reduction after 4 weeks to doses of 0.25 mg/kg/day and 0.375 mg/kg/day (22.5 mg maximum) of meloxicam and 15 mg/kg/day of naproxen.

The efficacy analysis used the ACR Pediatric, 30 responses definition, a composite of parent and investigator assessments, counts of active joints, and joints with limited range of motion, and erythrocyte sedimentation rate. The proportion of responses were similar in all three groups in both studies, and no difference was observed between the meloxicam dose groups.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

Meloxicam tablets USP are available as a light yellow, round, flat, uncoated tablet containing meloxicam 7.5 mg or a light yellow, oblong, biconvex, uncoated tablet containing meloxicam 15 mg. The 7.5 mg tablet is imprinted with letter L and 1, on one side and tablet code 75 on the other side. The 15 mg tablet is imprinted with letter L and 1, on one side and tablet code 15 on the other side.

Meloxicam Tablets USP 7.5 mg are available as follows:

NDC 29300-124-13, Bottles of 30

NDC 29300-124-01, Bottles of 100

NDC 29300-124-10, Bottles of 1,000

NDC 29300-124-50, Bottles of 5,000

Meloxicam Tablets USP 15 mg are available as follows:

NDC 29300-125-13, Bottles of 30

NDC 29300-125-01, Bottles of 100

NDC 29300-125-10, Bottles of 1,000

NDC 29300-125-50, Bottles of 5,000

**Storage:** Store at 20° to 25° (68° to 77° F) [see USP Controlled Room Temperature]. Keep Meloxicam Tablets USP in a dry place.

Dispense tablets in a tight container.

Keep this and all medications out of the reach of children.

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed.

**Additional Medication Guides can be obtained by calling Unichem at 1-866-562-4616.**

Inform patients, families or their caregivers of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy.

#### Cardiovascular Thrombotic Events

Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their health-care provider immediately [see Warnings and Precautions (5.1)].

#### Gastrointestinal Bleeding, Ulceration, and Perforation

Advise patients to report symptoms of ulceration and bleeding, including epigastric pain, dyspepsia, nausea, and hematemesis to their health-care provider. In the setting of concurrent use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for the signs and symptoms of GI bleeding [see Warnings and Precautions (5.2)].

#### Hepatotoxicity

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, instruct patients to stop Meloxicam tablets and seek immediate medical therapy [see Warnings and Precautions (5.3)].

#### Heart Failure and Edema

Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their health-care provider if such symptoms occur [see Warnings and Precautions (5.5)].

#### Anaphylactic Reactions

Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur [see Contraindications (4) and Warnings and Precautions (5.7)].

#### Seizure Susceptibility

Advise patients to stop Meloxicam tablets immediately if they develop any type of rash and to contact their health-care provider as soon as possible [see Warnings and Precautions (5.9)].

#### Fertility Evaluation

Advise females of reproductive potential who desire pregnancy that NSAIDs, including Meloxicam tablets, may be associated with a reversible delay in ovulation [see Use in Specific Populations (6.3)].

#### Fetal Toxicity

Inform pregnant women to avoid use of Meloxicam tablets and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closing of the fetal ductus arteriosus [see Warnings and Precautions (5.10) and Use in Specific Populations (6.3)].

#### Avoid Concurrent Use of NSAIDs

Inform patients that the concurrent use of Meloxicam tablets with other NSAIDs or salicylates (e.g., diffligan, ibuprofen) is not recommended due to the increased risk of gastrointestinal toxicity, and this use may increase in efficacy [see Warnings and Precautions (5.2) and Drug Interactions (7)]. Advise patients the NSAIDs may be present in "over the counter" medications for treatment of cold, fever, or insomnia.

#### Use of NSAIDs and Low-Dose Aspirin

Inform patients not to use low-dose aspirin concurrently with Meloxicam tablets until they talk to their health-care provider [see Drug Interactions (7)].

For current prescribing information, call Unichem at 1-866-562-4616.

Manufactured by:

UNICHEM LABORATORIES LTD.

Plotno Ind Estate,

Plotno, Baldeh, Goa 403511, India

Manufactured for:

 UNICHEM

PHARMACEUTICALS (USA), INC.

Habscock Heights, NJ 07064

07-8-09/2017

13009858

SPL MEDGUIDE

Medication Guide for Non-steroidal Anti-inflammatory Drugs (NSAIDs)
What is the most important information I should know about medicines called Non-steroidal Anti-inflammatory Drugs (NSAIDs)?
NSAIDs can cause serious side effects, including:
Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase:
with increasing doses of NSAIDs
with longer use of NSAIDs.
Do not take NSAIDs right before or after a heart surgery called a "coronary artery bypass graft (CABG).
Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack.
Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines:
aspirin during use
without warning symptoms
that may cause death.
The risk of getting an ulcer or bleeding increases with:
past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs
taking medicines called "corticosteroids," "anti-coagulants," "SSRIs," or "SNRIs"
increasing doses of NSAIDs
longer use of NSAIDs
smoking
drinking alcohol
elder age
poor health
advanced liver disease
bleeding problems.
NSAIDs should only be used:
exactly as prescribed
at the lowest dose possible for your treatment
for the shortest time needed.
What are NSAIDs?
NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain.
When should not take NSAIDs?
Do not take NSAIDs:
if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs, or before or after heart bypass surgery.
Before taking NSAIDs, tell your healthcare provider about all of your medical conditions, including if you:
have liver or kidney problems
have high blood pressure
have asthma
are pregnant or plan to become pregnant. Talk to your healthcare provider if you are considering taking NSAIDs during pregnancy. You should not take NSAIDs after 29 weeks of pregnancy.
Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements. NSAIDs and some other medicines can interact with each other and cause serious side effects. Do not start taking any new medicine without talking to your healthcare provider first.
What are the possible side effects of NSAIDs?
NSAIDs can cause serious side effects, including:
See "What is the most important information I should know about medicines called Non-steroidal Anti-inflammatory Drugs (NSAIDs)?"
new or worse high blood pressure
heart failure
liver problems including liver failure
kidney problems including kidney failure
low red blood cells (anemia)
bleeding ulcers, tears or rashes
life-threatening allergic reactions.
Other side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heartburn, nausea, headache, and dizziness.
Get emergency help right away if you get any of the following symptoms:
shortness of breath or trouble breathing
chest pain
dizziness
weakness in one part or side of your body
sudden speech
swelling of the face or throat.
Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms:
stomach and or weaker than usual
diarrhea
dizziness
your skin or eyes look yellow
indigestion or stomach pain
like-like symptoms
vomit blood
there is blood in your bowel movement or it is black and sticky like tar
unusual weight gain
skin rash or hives with fever
swelling of the arms, legs, hands and feet.
You take too much of your NSAID, call your healthcare provider or get medical help right away.
There are not the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Other information about NSAIDs:
Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines. Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.
General information about the safe and effective use of NSAIDs:
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them.
If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals.
Additional Medication Guides can be obtained by calling Unichem at 1-866-562-4616.
The other trademarks referenced are owned by third parties not affiliated with Unichem Laboratories Limited.
Manufactured by:
UNICHEM LABORATORIES LTD.
Plovdiv, Bulgaria.
UNICHEM PHARMACEUTICALS (USA), INC.
Basking Ridge, NJ 07004
US 509529

This Medication Guide has been approved by the U.S. Food and Drug Administration.
Revised: September 2017

PRINCIPAL DISPLAY PANEL
DRUG: meloxicam
GENERIC: meloxicam
DOSAGE: TABLET
ADMINISTRATION: ORAL
NDC: 70518-0031-0
NDC: 70518-0031-1
NDC: 70518-0031-2
COLOR: yellow
SHAPE: ROUND
SCORE: No score
SIZE: 7 mm
IMPRINT: U/L 7.5
PACKAGING: 30 in 1 BLENTER PACK
PACKAGING: 60 in 1 BOTTLE PLASTIC
PACKAGING: 90 in 1 BOTTLE PLASTIC
ACTIVE INGREDIENT(S):
• MELoxicAM 7.5mg in 1
(INACTIVE INGREDIENT(S):
• CELLULOSE, MICROCRYSTALLINE
• Povidone K18
• SILICON DIOXIDE
• MAGNESIUM STEARATE
• Croscopolledone
• Lactose monohydrate
• TROSEDium CITRATE DRYDRATE

Meloxicam
7.5 mg Tablet Qty: 30
ID #: U/L 7.5 Expires:
NDC #: 70518-0031-00 Shape: Round
LOT #: Ref #: 29300-0124-10
MFC: Unichem Pharma, Inc., Rochelle Park, NJ 07962
RX ONLY
Directions For Use: See Package Insert
Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [See USP]
Repackaged by:
RemedyRepack Inc., Indiana, PA 15701, 1-724-465-8792

Meloxicam
7.5 mg Tablet Qty: 60
ID #: U/L 7.5 Expires:
NDC #: 70518-0031-01 Shape: Round
LOT #: Ref #: 29300-0124-10
MFC: Unichem Pharma, Inc., Rochelle Park, NJ 07962
RX ONLY
Directions For Use: See Package Insert
Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F) [See USP]
Repackaged by:
RemedyRepack Inc., Indiana, PA 15701, 1-724-465-8792

**Meloxicam****7.5 mg Tablet**Qty: **90**
 ID #: U.L.7.5  
 NDC #: 70518-0031-02  
 LOT #:  
 MFG: Unichem Pharma, Inc., Rochelle Park, NJ 07862  
**RX ONLY**

 Expires:  
 Shape: Round  
 Ref #: 29300-0124-10

 Directions For Use: See Package Insert  
 Store at 20-25°C (68-77°F), excursions permitted to 15-30°C  
 (59-86°F) [See USP]  
 Repackaged by:  
 RemedyPack Inc., Indiana, PA 15701 1-724-465-8782


| MELOXICAM                                       |   |                      |                           |
|---|---|----------------------|---------------------------|
| meloxicam tablet                                |   |                      |                           |
| Product Information                             |   |                      |                           |
| Product Type                                    | REMEDYPACK (REMEDYPACK LABEL)                                       | NDC Code (Owner)     | NDC 70518-0031-02 (90-02) |
| Route of Administration                         | ORAL  |                      |                           |
| Active Ingredient/Active Moiety                 |   |                      |                           |
| Ingredient Name                                 | Ratio of Strength   | Strength             |                           |
| MELOXICAM (UNE VEGICIN/VEGICIN/VEGICIN/VEGICIN) | MELOXICAM   | 7.5 mg               |                           |
| Inactive Ingredients                            |   |                      |                           |
| Ingredient Name                                 | Strength  |                      |                           |
| CELLULOSE, MICROCRYSTALLINE (UNE 020200103)     |   |                      |                           |
| DIHYDROGENATED COLLOIDAL SILICA (UNE 020200103) |   |                      |                           |
| LACTOSE MONOHYDRATE (UNE 020200103)             |   |                      |                           |
| MAGNESIUM STEARATE (UNE 020200103)              |   |                      |                           |
| POLYBUTYLENE ADIPATE (UNE 020200103)            |   |                      |                           |
| POLYVINYL PIPERIDINE (UNE 020200103)            |   |                      |                           |
| TITANIUM DIOXIDE (UNE 020200103)                |   |                      |                           |
| Product Characteristics                         |   |                      |                           |
| Color   | White   | Score                | no score                  |
| Shape   | ROUND   | Size                 | 7mm                       |
| Imprint   |   | Imprint Code         | UN 75                     |
| Contains  |   |                      |                           |
| Packaging                                       |   |                      |                           |
| # of Items Code                                 | Package Description   | Marketing Start Date | Marketing End Date        |
| 1   | NDC 70518-0031-02 in 100 TABLETS, Type 0, Not a Combination Product | 02/20/06             |                           |
| 3   | NDC 70518-0031-03 in 300 TABLETS, Type 0, Not a Combination Product | 02/20/06             |                           |
| 6   | NDC 70518-0031-06 in 600 TABLETS, Type 0, Not a Combination Product | 02/20/06             |                           |
| Marketing Information                           |   |                      |                           |
| Marketing Category                              | Application Number and Monograph Classification                     | Marketing Start Date | Marketing End Date        |
| ANDA  | ANDA071927  | 02/20/06             |                           |
| <b>Labeler</b> - REMEDYPACK INC.(0052255)       |   |                      |                           |

Revise #: 2/2020

REMEDYPACK, INC.